{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hatten SJ"],"funding":["American Cancer Society","Genentech","Penn State College of Medicine","Cancer Council Tasmania","Penn State Hershey Cancer Institute","NCI NIH HHS","National Institutes of Health","Janssen Pharmaceuticals"],"pagination":["100909"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8971834"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(3)"],"pubmed_abstract":["<h4>Purpose</h4>The abscopal effect is defined when a form of local therapy causes tumor regression of both the target lesion and any untreated tumors. Herein cases of the abscopal effect were systematically reviewed and a patient-level data analysis was performed for clinical predictors of both duration of response and survival.<h4>Methods and materials</h4>The Population, Intervention, Control, Outcome, Study (PICOS) design approach, Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) literature selection process, and Meta-analysis of Observational Studies in Epidemiology (MOOSE) were used to find articles published before September 2019 in MEDLINE/PubMed and Google Scholar. Inclusion criteria were (1) population: patients with reported abscopal response; (2) intervention: documented treatment(s); (3) control: none; (4) outcomes: overall and progression-free survival; and (5) setting: retrospective case reports. Time from treatment until abscopal response and time from abscopal response until progression/death were calculated. Univariate and multivariate analyses were conducted for survival outcomes.<h4>Results</h4>Fifty studies (n = 55 patients) were included. Median age was 65 years (interquartile range [IQR], 58-70) and 62% were male. Fifty-four (98%) patients received radiation therapy, 34 (62%) received radiation therapy alone, 5 (9.1%) underwent surgery, 4 (7.3%) received chemotherapy, and 11 (20%) received immunotherapy. Median total dose was 32 Gy (IQR, 25.5-48 Gy) and median dose per fraction was 3 Gy (IQR, 2-7.2). Median time until abscopal response was 4 months (IQR, 1-5; min 0.5, max 24). At 5 years, overall survival was 63% and distant progression-free survival was 45%. No variables had statistical significance in predicting duration of response or survival.<h4>Conclusions</h4>Almost all reported cases of the abscopal response are after radiation therapy; however, there are no known predictors of duration of response or survival in this population."],"journal":["Advances in radiation oncology"],"pubmed_title":["A Patient-Level Data Meta-analysis of the Abscopal Effect."],"pmcid":["PMC8971834"],"funding_grant_id":["P30 CA008748","LRP 1 L30 CA231572-01","CSDG-20-013-01-CCE","L30 CA231572"],"pubmed_authors":["Liao J","Trifiletti DM","Zaorsky NG","Siva S","Sha CM","Holder SL","McBride SM","Hatten SJ","Lehrer EJ","Palma D"],"additional_accession":[]},"is_claimable":false,"name":"A Patient-Level Data Meta-analysis of the Abscopal Effect.","description":"<h4>Purpose</h4>The abscopal effect is defined when a form of local therapy causes tumor regression of both the target lesion and any untreated tumors. Herein cases of the abscopal effect were systematically reviewed and a patient-level data analysis was performed for clinical predictors of both duration of response and survival.<h4>Methods and materials</h4>The Population, Intervention, Control, Outcome, Study (PICOS) design approach, Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) literature selection process, and Meta-analysis of Observational Studies in Epidemiology (MOOSE) were used to find articles published before September 2019 in MEDLINE/PubMed and Google Scholar. Inclusion criteria were (1) population: patients with reported abscopal response; (2) intervention: documented treatment(s); (3) control: none; (4) outcomes: overall and progression-free survival; and (5) setting: retrospective case reports. Time from treatment until abscopal response and time from abscopal response until progression/death were calculated. Univariate and multivariate analyses were conducted for survival outcomes.<h4>Results</h4>Fifty studies (n = 55 patients) were included. Median age was 65 years (interquartile range [IQR], 58-70) and 62% were male. Fifty-four (98%) patients received radiation therapy, 34 (62%) received radiation therapy alone, 5 (9.1%) underwent surgery, 4 (7.3%) received chemotherapy, and 11 (20%) received immunotherapy. Median total dose was 32 Gy (IQR, 25.5-48 Gy) and median dose per fraction was 3 Gy (IQR, 2-7.2). Median time until abscopal response was 4 months (IQR, 1-5; min 0.5, max 24). At 5 years, overall survival was 63% and distant progression-free survival was 45%. No variables had statistical significance in predicting duration of response or survival.<h4>Conclusions</h4>Almost all reported cases of the abscopal response are after radiation therapy; however, there are no known predictors of duration of response or survival in this population.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May-Jun","modification":"2025-08-23T03:04:54.411Z","creation":"2025-04-06T14:50:00.742Z"},"accession":"S-EPMC8971834","cross_references":{"pubmed":["35372719"],"doi":["10.1016/j.adro.2022.100909"]}}